Ultraviolet B activated 1,25(OH)(2)D affects the level of fibroblast growth factor-23 in human.
نویسندگان
چکیده
Fibroblast growth factor 23 (FGF-23) is known as a phosphaturic factor regulating phosphate homeostasis. Several studies suggest that dietary phosphate, serum phosphate and 1,25-dihydroxyvitamin D [1,25(OH)(2)D] are candidate regulators of FGF-23. While the human studies, which modulated the dietary or serum phosphate showed in rather controversial results, manipulation of the active vitamin D definitely affected FGF-23 in animals. This study was conducted to elucidate the relationship between active vitamin D directly stimulated by ultraviolet B (UVB) exposure and FGF-23 level in human. Ten healthy young adults were recruited to get the UVB exposure thrice a week at sub-minimal erythemal dose with gradual increment by 10% only for 4 weeks. Serum calcium, phosphate, mineral-related hormones and bone turnover markers were analyzed before and after the UVB exposure every 4 week for 12 whole weeks. Twenty five-hydroxyvitamin D [25(OH)D] increased by 115% (19.8 ng/mL to 40.5 ng/mL, p < 0.001) after 4 weeks of UVB exposure. While 1,25(OH)(2)D increased by 75% (49.9 pg/mL to 64.4 pg/mL, p < 0.001) then both level decreased after 4 weeks of withdrawal. C-telopeptide peaked at 2nd week then decreased, while osteocalcin increased gradually. FGF-23 started to increase from the 4th week of UVB exposure then significantly at the 4th week after withdrawal of UVB (27.8 pg/mL to 41.4 pg/mL, p < 0.05). UVB exposure effectively increased 1,25(OH)(2)D with delayed stimulatory effect on FGF-23. This result could support the regulatory loop of 1,25(OH)(2)D and FGF-23 in human, FGF-23 regulation by 1,25(OH)(2)D.
منابع مشابه
Evaluation of serum FGF23 in patients with beta-thalassemia major compared to healthy population and its associated factors
Background: The role of phosphate hemostasis in development of thalassemia bone disease has not been extensively studied yet. Due to the lack of sufficient human studies about the changes of serum Fibroblast growth factor-23(FGF23) in patients with beta-thalassemia major as the first step of investigating the role of FGF23 in thalassemia bone disease, the present study aimed to investigate the ...
متن کاملFibroblast growth factor-23 abolishes 1,25-dihydroxyvitamin D₃-enhanced duodenal calcium transport in male mice.
Despite being widely recognized as the important bone-derived phosphaturic hormone, whether fibroblast growth factor (FGF)-23 modulated intestinal calcium absorption remained elusive. Since FGF-23 could reduce the circulating level of 1,25-dihydroxyvitamin D₃ [1,25(OH)₂D₃], FGF-23 probably compromised the 1,25(OH)₂D₃-induced intestinal calcium absorption. FGF-23 may also exert an inhibitory act...
متن کاملFibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D.
The regulation of the phosphaturic factor fibroblast growth factor 23 (FGF23) is not well understood. It was found that administration of 1,25-dihydroxyvitamin D(3) (1,25[OH](2)D(3)) to mice rapidly increased serum FGF23 concentrations from a basal level of 90.6 +/- 8.1 to 213.8 +/- 14.6 pg/ml at 8 h (mean +/- SEM; P < 0.01) and resulted in a four-fold increase in FGF23 transcripts in bone, the...
متن کاملCirculating fibroblast growth factor 23 in children on peritoneal dialysis is associated with effective dialysis.
Our purpose was to assess the relationship between serum fibroblast growth factor 23 (FGF23) and left ventricular function, carotid intima-media thickness (CIMT) and laboratory features in children on peritoneal dialysis (PD). The study population consisted of 17 patients (11 female; median age 7.83 years, range 0.66-17.75) undergoing PD for 22 months (range 2-98). Serum FGF23, serum phosphorus...
متن کاملFibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the "trade-off" hypothesis.
The discovery of fibroblast growth factor 23 (FGF23) has clarified much of our understanding of abnormalities in phosphorus and vitamin D metabolism in chronic kidney disease (CKD). FGF23 is a bone-derived hormone that promotes phosphaturia and decreases the synthesis of 1,25-dihydroxyvitamin D (1,25(OH)(2)D). The primary systemic stimuli of FGF23 secretion are increased 1,25(OH)(2)D levels and...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Endocrine journal
دوره 60 1 شماره
صفحات -
تاریخ انتشار 2013